Anti-Inflammatory Lipid Mediators in Asthma

Summary

The purpose of this study is to demonstrate the efficacy and safety of 10-nitro-9(E)-octadec-9-enoic acid (CXA-10) in obese adult asthmatics. The study's hypothesis is that 150 mg/day of CXA-10 for 12 weeks will alleviate obesity-related airway hyper-reactivity in obese adult asthmatics.

Timeline

Start

—

Primary completion

2021-04

Completion

2021-04

Drugs

Indications